Barcelona

• A Study to Investigate the Safety and Effectiveness of RO7759065 in Combination with Atezolizumab in Participants with Locally Advanced or M … Ended
  2024-513391-17-00 1 2025-05-27 Locally Advanced or Metastatic Solid Tumors
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DG … Ended
  2023-503996-38-00 1 2025-05-21 Advanced or metastatic solid tumors
• A Phase 2 Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2024-516889-11-00 4 2025-05-21 non-small cell lung cancer (NSCLC)
• A Study on Oral and Intranasal Forms in Healthy Volunteers using Pharmacokinetic Modeling Ended
  2024-515461-34-00 3 2025-05-14 healthy volunteers
• A clinical trial to compare three oral treatments and a placebo in preventing skin reactions caused by histamine in healthy volunteers Ended
  2024-516569-35-00 6 2025-05-09 Allergy
• A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma Ended
  2024-513439-25-00 1 2025-04-30 Relapsed/Refractory Multiple Myeloma
• A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KR … Ended
  2024-516699-14-00 7 2025-04-23 Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenoca
• Phase 1 trial of LAVA-1266, a CD123-targeting bispecific Vγ9Vδ2-T cell engager, in patients with CD123 positive relapsed/refractory (R/R) ac … Ended
  2024-518831-12-00 1 2025-04-15 CD123 positive R/R AML and intermediate risk, high risk, or extremely
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 Ended
  2024-515452-20-00 4 2025-04-01 Narcolepsy Type 2
• A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Th … Ended
  2024-515539-31-00 4 2025-04-01 Alzheimer’s disease dementia
• Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors Ended
  2024-513563-75-00 1 2025-03-20 Metastatic or advanced malignant solid tumors
• A study to evaluate safety and efficacy of Empasiprubart in adults with Dermatomyositis Ended
  2023-508337-14-00 4 2025-03-18 Myositis, Dermatomyositis
• AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation Ended
  2024-515391-12-00 1 2025-03-15 Advanced Solid Tumors with AKT1 E17K Mutation
• Phase 1/2 Study of Cobolimab plus Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors Ended
  2024-511350-41-00 9 2025-03-13 Relapsed/Refractory Tumors
• Phase I clinical trial to evaluate the pharmacokinetics, safety and tolerability of repeated topical application of PARENTIDE in healthy vol … Ended
  2024-516833-11-00 3 2025-03-12 Healthy volunteers
• A Study of ZL-1218 with or without Pembrolizumab in Subjects with Advanced Solid Tumor Cancers to Find a Suitable Dose and to Test How Diffe … Ended
  2022-503102-20-00 1 2025-03-10 Advanced solid tumors
• A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2024-512380-32-00 1 2025-03-03 esophageal, gastric, or gastroesophageal junction adenocarcinoma
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended
  2024-512505-66-00 10 2025-03-03 HIV-1 Infection
• An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic … Ended
  2024-517061-16-01 4 2025-02-27 Focal onset seizures or primary generalized tonic-clonic seizures
• A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT … Ended
  2023-505908-28-00 2 2025-02-26 Chronic spontaneous urticaria
• Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults with Type 2 Diabetes M … Ended
  2024-512562-34-00 4 2025-02-24 Type 2 Diabetes Mellitus
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac … Ended
  2023-508959-39-00 5 2025-02-20 Moderate to Severe Plaque Psoriasis
• An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination wi … Ended
  2024-512670-10-00 9 2025-02-13 Unresectable or Metastatic Melanoma
• Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for … Ended
  2023-509257-31-00 1 2025-02-12 Alzheimer’s Disease in Individuals with Down Syndrome

Showing 2,569–2,592 of 3,391 trials